Guidance, NICE advice and quality standards in development | Guidance

Showing 201 to 210 of 366

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance	TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain	HealthTech guidance	TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	4 September 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]	Technology appraisal guidance	TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]	Technology appraisal guidance	TBC